Compare GSK plc (GSK) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? GSK plc trades at $52.7 (market cap $101.34B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.91. The key difference: GSK plc pays a 3.49% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and GSK plc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| GSK | YINN | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $56.62 |
52-Week Low | $36.20 | $21.45 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $27.85, up 7.28% with strong bullish technical signals from moving averages and oscillators. The ETF benefits from China's tech-focused stimulus and AI infrastructure investments, though key financial ratios remain unavailable for this leveraged product. Recent news highlights China's $295 billion AI buildout plan and strong export growth, creating favorable conditions for Chinese equities exposure.
The outlook remains cautiously optimistic given China's economic stimulus and tech sector momentum, but YINN's 3x leverage amplifies both gains and losses. Key risks include U.S.-China trade tensions and the inherent volatility of leveraged ETFs. Investors should consider this as a tactical trading vehicle rather than long-term holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
